查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
孕产妇心理健康市场--全球产业分析、规模、份额、成长、趋势、区域前景、预测（2023-2030）-（按适应症、治疗方法、地区、公司）
市场调查报告书
商品编码
1358262

孕产妇心理健康市场--全球产业分析、规模、份额、成长、趋势、区域前景、预测（2023-2030）-（按适应症、治疗方法、地区、公司）

Maternal Mental Health Market - Global Maternal Mental Health Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2030 - (By Disease Indication Coverage, By Therapy Coverage, By Geographic Coverage and By Company)
出版日期: | 出版商: Fairfield Market Research | 英文 270 Pages | 商品交期: 2-5个工作天内

价格
简介目录

到 2030 年底，全球孕产妇心理健康市场规模预计将达到 400 亿美元的重要估值，2023 年至 2030 年复合年增长率稳定达到 28%。 这一前所未有的增长是由政府增加旨在降低孕产妇死亡率的资金、产后抑郁症发病率急剧上升、扩大认识计划以及不断努力加强与孕产妇心理健康相关的做法推动的。

孕产妇心理健康市场的快速扩张是由积极的报销情况、产后忧郁症 (PPD) 患病率上升、广泛宣传举措的实施以及强大可靠的医疗基础设施等因素推动的。由极其重要的因素组合支持。

产后忧郁症是一种对产妇产后心理健康影响重大的疾病，由于其发生广泛、影响严重，在孕产妇心理健康领域占有最大的市场份额。

人际关係治疗 (IPT) 以其在解决基于关係的压力源和增强围产期产妇福祉方面的有效性而闻名，已成为孕产妇心理健康市场的领先治疗方法。

受益于专业护理、咨询服务和支持团体的增加，北美继续处于孕产妇心理健康市场的前沿。 该地区先进的医疗基础设施和积极主动的孕产妇心理健康方法奠定了其领先地位。

亚太地区已成为成长最快的市场，人们对孕产妇心理健康问题的认识不断提高。 该地区的经济成长改善了医疗保健基础设施、改善了医疗设施的使用以及对妇女健康的关注。

本报告调查了全球孕产妇心理健康市场，并提供了市场概况、按疾病适应症、治疗方法、地区划分的趋势以及进入市场的公司的竞争趋势。

目录

第 1 章执行摘要

第 2 章市场概述

  • 市场定义与细分
  • 市场动态
  • 价值链分析
  • 波特五力分析
  • 新冠肺炎 (COVID-19) 影响分析
  • 乌克兰和俄罗斯之间衝突的影响
  • 经济概况
  • PESTLE分析

第 3 章 2018-2030 年全球孕产妇心理健康市场展望

  • 2018-2030 年全球孕产妇心理健康市场前景按适应症划分、金额（十亿美元）
  • 2018-2030 年全球孕产妇心理健康市场前景按治疗方法、金额（十亿美元）
  • 2018-2030 年全球孕产妇心理健康市场展望按地区、金额（十亿美元）

第 4 章 2018-2030 年北美孕产妇心理健康市场前景

第 5 章欧洲孕产妇心理健康市场展望，2018-2030

第 6 章亚太地区孕产妇心理健康市场展望，2018-2030

第 7 章拉丁美洲孕产妇心理健康市场展望，2018-2030

第 8 章中东与非洲孕产妇心理健康市场前景，2018-2030

第 9 章竞争态势

  • 疾病适应症与用途热图
  • 製造商和应用程式的热图
  • 2022 年公司市占率分析
  • 竞争力仪表板
  • 公司简介
    • Pfizer, Inc.
    • Lipocine, Inc.
    • Viatris Inc.
    • GlaxoSmithKline plc
    • Alembic Pharmaceuticals Limited
    • Mallinckrodt, Inc.
    • Sage Therapeutics, Inc.
    • Bold Health
    • Bausch Health Companies Inc.
    • Magellan Health, Inc.

第 10 章附录

简介目录

Global Maternal Mental Health Market Poised for Remarkable Growth, Projected to Reach US$40 Billion by 2030.

The global maternal mental health market is on track to achieve a substantial valuation of US$40 billion by the close of 2030, driven by a robust compound annual growth rate (CAGR) of 28% during the period from 2023 to 2030. This unprecedented growth is attributed to several key factors, including increased government funding aimed at reducing maternal mortality, a surge in the incidence of postpartum depression, expanding awareness programs, and ongoing efforts to enhance practices related to maternal mental health.

Market Insights in Brief

The maternal mental health market's rapid expansion is underpinned by a combination of pivotal drivers, including positive reimbursement scenarios, a rising prevalence of postpartum depression (PPD), the implementation of widespread awareness initiatives, and the presence of a robust and reliable healthcare infrastructure.

Postpartum depression, a condition with significant implications for the mental well-being of postpartum mothers, commands the largest market share in the maternal mental health sector due to its widespread occurrence and profound impact.

Interpersonal therapy (IPT) has emerged as a leading therapeutic approach in the maternal mental health market, known for its effectiveness in addressing relationship-based stressors and enhancing maternal well-being during the perinatal period.

Regional Dynamics

North America remains at the forefront of the maternal mental health market, benefiting from enhanced accessibility to specialized care, counseling services, and support groups. The region's advanced healthcare infrastructure and proactive approach towards maternal mental health have contributed to its leadership position.

Asia Pacific, experiencing a surge in awareness about maternal mental health issues, is emerging as the fastest-growing market. The region's economic growth has led to improved healthcare infrastructure, increased access to medical facilities, and a growing emphasis on women's health.

Growth Drivers

  • 1. Growing Government Funds Targeting Reduced Maternal Mortality

Government investments in mental health services and support for pregnant and postpartum women have played a pivotal role in reducing the risk of maternal mental health disorders. These funds have led to the expansion of maternal mental health services, including early detection, counseling, specialized clinics, and awareness campaigns, thereby reducing stigma and encouraging more women to seek help during pregnancy and postpartum periods.

  • 2. Growing Incidences of Postpartum Depression

The rising prevalence of postpartum depression, coupled with improved screening and detection measures, has resulted in a higher demand for maternal mental health services. Timely intervention for postpartum depression is recognized as crucial to prevent long-term impacts on both mother and child well-being, further driving market growth.

Challenges

Mental Health Workforce Shortage

Despite the growing demand for mental health services during the perinatal period, a shortage of qualified experts remains a significant constraint. This scarcity leads to long wait times for appointments, limited access to specialized treatment, and delayed interventions, potentially affecting the health outcomes of pregnant and postpartum women.

Competitive Landscape

Key players in the maternal mental health market include: Lipocine, Inc., Pfizer, Inc., Viatris, Inc., Bold Health, GlaxoSmithKline Inc., Alembic Pharmaceuticals Limited, Mallinckrodt, Inc., Sage Therapeutics, Inc., Bausch Health Companies Inc., and Magellan Health, Inc.

The global maternal mental health market's remarkable growth trajectory underscores its pivotal role in safeguarding the well-being of mothers and the health and development of their children. As governments, healthcare providers, and the private sector continue to invest in this critical healthcare segment, the market is poised to make substantial strides in the years ahead.

Table of Contents

1. Executive Summary

  • 1.1. Global Maternal Mental Health Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2022
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. Covid-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Maternal Mental Health Market Outlook, 2018 - 2030

  • 3.1. Global Maternal Mental Health Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2030
    • 3.1.1. Key Highlights
      • 3.1.1.1. Postpartum Depression
      • 3.1.1.2. Dysthymia
      • 3.1.1.3. Pregnancy and Postpartum General Anxiety
      • 3.1.1.4. Pregnancy and Postpartum OCD
      • 3.1.1.5. Birth-Related PTSD
      • 3.1.1.6. Others
  • 3.2. Global Maternal Mental Health Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2030
    • 3.2.1. Key Highlights
      • 3.2.1.1. Antidepressants
        • 3.2.1.1.1. Selective serotonin reuptake inhibitors (SSRIs)
        • 3.2.1.1.2. Tricyclic antidepressants (TCAs)
        • 3.2.1.1.3. Other
      • 3.2.1.2. Interpersonal Psychotherapy (IPT)
      • 3.2.1.3. Cognitive Behavioural Therapy (CBT)
      • 3.2.1.4. Other
  • 3.3. Global Maternal Mental Health Market Outlook, by Region, Value (US$ Bn), 2018 - 2030
    • 3.3.1. Key Highlights
      • 3.3.1.1. North America
      • 3.3.1.2. Europe
      • 3.3.1.3. Asia Pacific
      • 3.3.1.4. Latin America
      • 3.3.1.5. Middle East & Africa

4. North America Maternal Mental Health Market Outlook, 2018 - 2030

  • 4.1. North America Maternal Mental Health Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2030
    • 4.1.1. Key Highlights
      • 4.1.1.1. Postpartum Depression
      • 4.1.1.2. Dysthymia
      • 4.1.1.3. Pregnancy and Postpartum General Anxiety
      • 4.1.1.4. Pregnancy and Postpartum OCD
      • 4.1.1.5. Birth-Related PTSD
      • 4.1.1.6. Others
  • 4.2. North America Maternal Mental Health Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2030
    • 4.2.1. Key Highlights
      • 4.2.1.1. Antidepressants
        • 4.2.1.1.1. Selective serotonin reuptake inhibitors (SSRIs)
        • 4.2.1.1.2. Tricyclic antidepressants (TCAs)
        • 4.2.1.1.3. Other
      • 4.2.1.2. Interpersonal Psychotherapy (IPT)
      • 4.2.1.3. Cognitive Behavioural Therapy (CBT)
      • 4.2.1.4. Other
    • 4.2.2. Market Attractiveness Analysis
  • 4.3. North America Maternal Mental Health Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 4.3.1. Key Highlights
      • 4.3.1.1. U.S. Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 4.3.1.2. U.S. Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 4.3.1.3. Canada Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 4.3.1.4. Canada Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Maternal Mental Health Market Outlook, 2018 - 2030

  • 5.1. Europe Maternal Mental Health Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2030
    • 5.1.1. Key Highlights
      • 5.1.1.1. Postpartum Depression
      • 5.1.1.2. Dysthymia
      • 5.1.1.3. Pregnancy and Postpartum General Anxiety
      • 5.1.1.4. Pregnancy and Postpartum OCD
      • 5.1.1.5. Birth-Related PTSD
      • 5.1.1.6. Others
  • 5.2. Europe Maternal Mental Health Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2030
    • 5.2.1. Key Highlights
      • 5.2.1.1. Antidepressants
        • 5.2.1.1.1. Selective serotonin reuptake inhibitors (SSRIs)
        • 5.2.1.1.2. Tricyclic antidepressants (TCAs)
        • 5.2.1.1.3. Other
      • 5.2.1.2. Interpersonal Psychotherapy (IPT)
      • 5.2.1.3. Cognitive Behavioural Therapy (CBT)
      • 5.2.1.4. Other
    • 5.2.2. BPS Analysis/Market Attractiveness Analysis
  • 5.3. Europe Maternal Mental Health Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 5.3.1. Key Highlights
      • 5.3.1.1. Germany Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 5.3.1.2. Germany Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 5.3.1.3. U.K. Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 5.3.1.4. U.K. Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 5.3.1.5. France Maternal Mental Health Market By Disease Indication, Value (US$ Bn), 2018 - 2030
      • 5.3.1.6. France Maternal Mental Health Market By Therapy, Value (US$ Bn), 2018 - 2030
      • 5.3.1.7. Italy Maternal Mental Health Market By Disease Indication, Value (US$ Bn), 2018 - 2030
      • 5.3.1.8. Italy Maternal Mental Health Market By Therapy, Value (US$ Bn), 2018 - 2030
      • 5.3.1.9. Turkey Maternal Mental Health Market By Disease Indication, Value (US$ Bn), 2018 - 2030
      • 5.3.1.10. Turkey Maternal Mental Health Market By Therapy, Value (US$ Bn), 2018 - 2030
      • 5.3.1.11. Russia Maternal Mental Health Market By Disease Indication, Value (US$ Bn), 2018 - 2030
      • 5.3.1.12. Russia Maternal Mental Health Market By Therapy, Value (US$ Bn), 2018 - 2030
      • 5.3.1.13. Rest Of Europe Maternal Mental Health Market By Disease Indication, Value (US$ Bn), 2018 - 2030
      • 5.3.1.14. Rest Of Europe Maternal Mental Health Market By Therapy, Value (US$ Bn), 2018 - 2030
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Maternal Mental Health Market Outlook, 2018 - 2030

  • 6.1. Asia Pacific Maternal Mental Health Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2030
    • 6.1.1. Key Highlights
      • 6.1.1.1. Postpartum Depression
      • 6.1.1.2. Dysthymia
      • 6.1.1.3. Pregnancy and Postpartum General Anxiety
      • 6.1.1.4. Pregnancy and Postpartum OCD
      • 6.1.1.5. Birth-Related PTSD
      • 6.1.1.6. Others
  • 6.2. Asia Pacific Maternal Mental Health Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2030
    • 6.2.1. Key Highlights
      • 6.2.1.1. Antidepressants
        • 6.2.1.1.1. Selective serotonin reuptake inhibitors (SSRIs)
        • 6.2.1.1.2. Tricyclic antidepressants (TCAs)
        • 6.2.1.1.3. Other
      • 6.2.1.2. Interpersonal Psychotherapy (IPT)
      • 6.2.1.3. Cognitive Behavioural Therapy (CBT)
      • 6.2.1.4. Other
    • 6.2.2. BPS Analysis/Market Attractiveness Analysis
  • 6.3. Asia Pacific Maternal Mental Health Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 6.3.1. Key Highlights
      • 6.3.1.1. China Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 6.3.1.2. China Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 6.3.1.3. Japan Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 6.3.1.4. Japan Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 6.3.1.5. South Korea Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 6.3.1.6. South Korea Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 6.3.1.7. India Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 6.3.1.8. India Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 6.3.1.9. Southeast Asia Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 6.3.1.10. Southeast Asia Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 6.3.1.11. Rest of Asia Pacific Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 6.3.1.12. Rest of Asia Pacific Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Maternal Mental Health Market Outlook, 2018 - 2030

  • 7.1. Latin America Maternal Mental Health Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2030
    • 7.1.1. Key Highlights
      • 7.1.1.1. Postpartum Depression
      • 7.1.1.2. Dysthymia
      • 7.1.1.3. Pregnancy and Postpartum General Anxiety
      • 7.1.1.4. Pregnancy and Postpartum OCD
      • 7.1.1.5. Birth-Related PTSD
      • 7.1.1.6. Others
  • 7.2. Latin America Maternal Mental Health Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2030
    • 7.2.1. Key Highlights
      • 7.2.1.1. Antidepressants
        • 7.2.1.1.1. Selective serotonin reuptake inhibitors (SSRIs)
        • 7.2.1.1.2. Tricyclic antidepressants (TCAs)
        • 7.2.1.1.3. Other
      • 7.2.1.2. Interpersonal Psychotherapy (IPT)
      • 7.2.1.3. Cognitive Behavioural Therapy (CBT)
      • 7.2.1.4. Other
    • 7.2.2. BPS Analysis/Market Attractiveness Analysis
  • 7.3. Latin America Maternal Mental Health Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 7.3.1. Key Highlights
      • 7.3.1.1. Brazil Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 7.3.1.2. Brazil Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 7.3.1.3. Mexico Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 7.3.1.4. Mexico Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 7.3.1.5. Argentina Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 7.3.1.6. Argentina Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 7.3.1.7. Rest of Latin America Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 7.3.1.8. Rest of Latin America Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Maternal Mental Health Market Outlook, 2018 - 2030

  • 8.1. Middle East & Africa Maternal Mental Health Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2030
    • 8.1.1. Key Highlights
      • 8.1.1.1. Postpartum Depression
      • 8.1.1.2. Dysthymia
      • 8.1.1.3. Pregnancy and Postpartum General Anxiety
      • 8.1.1.4. Pregnancy and Postpartum OCD
      • 8.1.1.5. Birth-Related PTSD
      • 8.1.1.6. Others
  • 8.2. Middle East & Africa Maternal Mental Health Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2030
    • 8.2.1. Key Highlights
      • 8.2.1.1. Antidepressants
        • 8.2.1.1.1. Selective serotonin reuptake inhibitors (SSRIs)
        • 8.2.1.1.2. Tricyclic antidepressants (TCAs)
        • 8.2.1.1.3. Other
      • 8.2.1.2. Interpersonal Psychotherapy (IPT)
      • 8.2.1.3. Cognitive Behavioural Therapy (CBT)
      • 8.2.1.4. Other
    • 8.2.2. BPS Analysis/Market Attractiveness Analysis
  • 8.3. Middle East & Africa Maternal Mental Health Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 8.3.1. Key Highlights
      • 8.3.1.1. GCC Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 8.3.1.2. GCC Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 8.3.1.3. South Africa Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 8.3.1.4. South Africa Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 8.3.1.5. Egypt Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 8.3.1.6. Egypt Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 8.3.1.7. Nigeria Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 8.3.1.8. Nigeria Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
      • 8.3.1.9. Rest of Middle East & Africa Maternal Mental Health Market by Disease Indication, Value (US$ Bn), 2018 - 2030
      • 8.3.1.10. Rest of Middle East & Africa Maternal Mental Health Market by Therapy, Value (US$ Bn), 2018 - 2030
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Disease Indication vs Application Heatmap
  • 9.2. Manufacturer vs Application Heatmap
  • 9.3. Company Market Share Analysis, 2022
  • 9.4. Competitive Dashboard
  • 9.5. Company Profiles
    • 9.5.1. Pfizer, Inc.
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Product Portfolio
      • 9.5.1.3. Financial Overview
      • 9.5.1.4. Business Strategies and Development
    • 9.5.2. Lipocine, Inc.
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Product Portfolio
      • 9.5.2.3. Financial Overview
      • 9.5.2.4. Business Strategies and Development
    • 9.5.3. Viatris Inc.
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Product Portfolio
      • 9.5.3.3. Financial Overview
      • 9.5.3.4. Business Strategies and Development
    • 9.5.4. GlaxoSmithKline plc
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Product Portfolio
      • 9.5.4.3. Financial Overview
      • 9.5.4.4. Business Strategies and Development
    • 9.5.5. Alembic Pharmaceuticals Limited
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Product Portfolio
      • 9.5.5.3. Financial Overview
      • 9.5.5.4. Business Strategies and Development
    • 9.5.6. Mallinckrodt, Inc.
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Product Portfolio
      • 9.5.6.3. Financial Overview
      • 9.5.6.4. Business Strategies and Development
    • 9.5.7. Sage Therapeutics, Inc.
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Product Portfolio
      • 9.5.7.3. Financial Overview
      • 9.5.7.4. Business Strategies and Development
    • 9.5.8. Bold Health
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Product Portfolio
      • 9.5.8.3. Financial Overview
      • 9.5.8.4. Business Strategies and Development
    • 9.5.9. Bausch Health Companies Inc.
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Product Portfolio
      • 9.5.9.3. Financial Overview
      • 9.5.9.4. Business Strategies and Development
    • 9.5.10. Magellan Health, Inc.
      • 9.5.10.1. Company Overview
      • 9.5.10.2. Product Portfolio
      • 9.5.10.3. Financial Overview
      • 9.5.10.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations